Mikkel Pedersen, based in Denmark, is currently a Chief Scientific Officer at Nykode Therapeutics, bringing experience from previous roles at Servier and Symphogen. Mikkel Pedersen holds a 2000 - 2003 PhD in Cancer @ Copenhagen University. With a robust skill set that includes Cell, Antibodies, Drug Discovery, In Vitro, Cell Biology and more, Mikkel Pedersen contributes valuable insights to the industry. Mikkel Pedersen has 2 emails on RocketReach.